Locomotor effects of imidazoline I 2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway

British Journal of Pharmacology

Volumn 143, Issue 8, 2004, Pages 952-959

  MacInnes, Nicholas ^a   Duty, Susan ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

2 BFI; Deprenyl; Imidazoline I 2 site; in vivo; Lazabemide; Moclobemide; Monoamine oxidase; Parkinson's disease; Rat

Indexed keywords

2 (2 BENZOFURANYL) 2 IMIDAZOLINE; 2 (2 IMIDAZOLIN 2 YL)QUINOLINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPHETAMINE; ANTIPARKINSON AGENT; BENSERAZIDE; DESIPRAMINE; DOPAMINE; IMIDAZOLINE I2 RECEPTOR; LAZABEMIDE; LEVODOPA; LIGAND; MOCLOBEMIDE; MONOAMINE OXIDASE B INHIBITOR; OXIDOPAMINE; PARGYLINE; SELEGILINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; NEUROLOGIC DISEASE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; LIGANDS; MALE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; NEURAL PATHWAYS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DRUG; SUBSTANTIA NIGRA;

EID: 11244252922     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706019     Document Type: Article

References (47)

1. 2 imidazoline-preferring receptors. Br. J. Pharmacol., 114, 837-845.
2. AUBIN, N., BARNEOUD, P., CARTER, C., CAILLE, D., SONTAG, N., MARC, C., LOLIVIER, J., GARDES, A., PERRON, C., LE KIM, A., CHARIERAS, T., BURNIER, P., PUECH, F., JEGHAM, S., GEORGE, P., SCATTON, B. & CURET, O. (2004). New developments SL25.1131, a new, reversible and mixed inhibitor of MAO-A and MAO-B: biochemical and behavioural profile. J. Pharmacol. Exp. Ther., 310, 1171-1182.
3. BARBEAU, A. (1981). The use of L-DOPA in Parkinson's disease: a 20 year follow up. Trends Pharmacol. Sci., 2, 297-301.
4. BURKWARD, W.P., BONETTI, E.P., DA PRADA, M., MARTIN, J.R., POLC, P., SCHAFFNER, R., SCHERSCHLICT, R., HEFTI, F., MULLER, R.K.M., WYSS, P. & HAEFELY, W.E. (1989). Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther., 248, 391-399.
5. BUTCHER, S.P., FAIRBROTHER, I.S., KELLY, J.S. & ARBUTHNOTT, G.W. (1990). Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J. Neurochem., 55, 981-988.
6. CHADHA, A., DAWSON, L.G., JENNER, P.G. & DUTY, S. (2000). Effect of unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway on GABA(A) receptor subunit gene expression in the rodent basal ganglia and thalamus. Neuroscience, 95, 119-126.
7. 2 sites. Ann. N. Y. Acad. Sci., 763, 153-156.
8. CHOPIN, P., COLPAERT, F.C. & MARIEN, M. (1999). Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther., 288, 798-804.
9. DA PRADA, M., KETTLER, R., KELLER, H.H., KYBURZ, E. & HAEFELY, W.E. (1987). Ro 19-6327, a novel highly selective and reversible MAO-B inhbitor. Pharmacol. Toxicol., 60 (Suppl. 1), 10.
10. EGLEN, R.M., HUDSON, A.L., KENDALL, D.A., NUTT, D.J., MORGAN, N.G., WILSON, V.G. & DILLON, M.P. (1998). 'Seeing through a glass darkly': casting a light on imidazoline 'I' sites. Trends Pharmacol. Sci., 19, 381-390.
11. FANG, J. & YU, P.H. (1994). Effects of 1-deprenyl, its analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology, 33, 763-768.
12. FINBERG, J.P. & YOUDIM, M.B. (1994). Pharmacological actions of 1-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors. Clin. Pharmacol Ther., 56, 725-733.
13. GARGALIDIS-MOUDANOS, C., PIZZINAT, N., JAVOY-AGID, F., REMAURY, A. & PARINI, A. (1997). I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease. Neurochem Int., 30, 31-36.
14. HEERINGA, M.J., D'AGOSTINI, D., DEBOER, P., DAPRADA, M. & DAMSMA, G. (1997). Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behaviour. J. Neural Transm., 104, 593-603.
15. HEFTI, F., MELAMED, E., SAHAKIAN, B.J. & WURTMAN, R.J. (1980). Circling behaviour in rats with partial, unilateral nigrostriatal lesions: effect of amphetamine, apomorphine and DOPA. Pharmacol. Biochem. Behav., 12, 185-188.
16. HEIKKILA, R.E., CABBAT, F.S., MANZINO, L. & DUVOISIN, R.C. (1981). Potentiation by deprenil of 1-dopa induced circling in nigral-lesioned rats. Pharmacol. Biochem. Behav., 15, 75-79.
17. HUDSON, A.L., GOUGH, R.E., TYACKE, R.J., LIONE, L., LALIES, M., LEWIS, J., HUSBANDS, S., KNIGHT, P., MURRAY, F., HUTSON, P. & NUTT, D.J. (1999). Novel selective compounds for the investigation of imidazoline receptors. Ann N. Y. Acad. Sci., 881, 81-91.
18. IRAVANI, M.M., KASHEFI, K., MANDER, P., ROSE, S. & JENNER, P. (2002). Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience, 110, 49-58.
19. JANKOVIC, J. (2000). Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin. Neuropharmacol., 23, 252-261.
20. 2 site ligand, 2-BFI. J. Psychopharmacol., 10, 273-278.
21. KATO, T., DONG, B., ISHII, K. & KINENUCHI, H. (1986). Brain dialysis in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J. Neurochem., 46, 1277-1282.
22. 2 site selective ligands. Ann. N. Y. Acad. Sci., 881, 114-117.
23. LAMENSDORF, I., PORAT, S., SIMANTOV, R. & FINBERG, J.P.M. (1999). Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br. J. Pharmacol., 126, 997-1002.
24. LE WITT, P.A. & NYHOLM, D. (2004). New developments in levodopa therapy. Neurology, 62, S9-S16.
25. 2 receptors. Eur. J. Pharmacol., 353, 123-135.
26. 2 sites. Eur. J. Pharmacol., 428, 221-225.
27. 2-site ligands, MAOIs, β-carbolines, agmatine and ibogaine. Br. J. Pharmacol., 135, 1227-1234.
28. MICHEL, M.C. & ERNSBERGER, P. (1992). Keeping an eye on the I site: Imidazoline-preferring receptors. Trends Pharmacol. Sci., 13, 270-369.
29. MURRAY, T.K., MESSENGER, M.J., WARD, M.A., WOODHOUSE, S., OSBORNE, D.J., DUTY, S. & O'NEILL, M.J. (2002). Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol. Biochem. Behav., 73, 455-466.
30. NEUSCH, C., SCHNIERLE, S. & MOSER, A. (1997). Selegiline induces dopamine release through ATP-sensitive potassium channels in the rat caudate-putamen in vitro. Neurochem. Int., 31, 307-311.
31. NUTT, D.J., FRENCH, N., HANDLEY, S.L., HUDSON, A., HUSBANDS, S., JACKSON, H., JORDAN, S., LALIES, M.D., LEWIS, J., LIONE, L.A., MALLARD, N. & PRATT, J. (1995). Functional studies of specific imidazoline-2 receptor ligands. Ann. N. Y. Acad. Sci., 763, 125-139.
32. NUTT, J.G. (1990). Levodopa-induced dyskinesia: review, observations and speculation. Neurology, 40, 340-345.
33. O'NEILL, M.J., MURRAY, T.K., WHALLEY, K., WARD, M.A., HICKS, C.A., OSBORNE, D.J. & SKOLNICK, P. (2004). Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease. Eur. J. Pharmacol., 486, 163-174.
34. 2-imidazoline receptors in rat liver. Br. J. Pharmacol., 121, 901-912.
35. PARKINSON STUDY GROUP (1994). A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Arch. Neurol., 51, 342-347.
36. PARKINSON STUDY GROUP (1996). Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann. Neurol., 40, 99-107.
37. PARKINSON STUDY GROUP (2004). A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol., 61, 561-566.
38. PAXINOS, G. & WATSON, C. (1998). The Rat Brain in Stereotaxic Coordinates. UK: Academic Press.
39. PRAT, G., PEREZ, V., RUBI, A., CASAS, M. & UNZETA, M. (2000). The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats. J. Neural Transm., 107, 409-417.
40. PYCOCK, C.J. (1980). Turning behaviour in animals. Neuroscience, 5, 461-514.
41. RADDATZ, R., PARINI, A. & LANIER, S.M. (1997). Localization of the imidazoline binding domain on monoamine oxidase B. Mol. Pharmacol., 52, 549-553.
42. 2-imidazoline-binding proteins using monoamine oxidase-deficient mouse models. Mol. Pharmacol., 58, 1085-1090.
43. REYNOLDS, G.P., BOULTON, R.M., PEARSON, S.J., HUDSON, A.L. & NUTT, D.J. (1996). Imidazoline binding sites in Huntington's and Parkinson's disease putamen. Eur J Pharmacol., 301, R19-R21.
44. ROBINSON, E.S., TYACKE, R.J., NUTT, D.J. & HUDSON, A.L. (2002). Distribution of [(3)H]BU224, a selective imidazoline I(2) binding site ligand, in rat brain. Eur. J. Pharmacol., 450, 55-60.
45. SASTRE-COLL, A., ESTEBAN, S., MIRALLES, A., ZANETTI, R. & GARCIA-SEVILLA, J.A. (2001). The imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline is a dopamine releasing agent in the rat striatum in vivo. Neurosci. Lett., 301, 29-32.
46. STOCCHI, F., NORDERA, G. & MARSDEN, C.D. (1997). Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin. Neuropharmacol., 20, 95-115.
47. UNGERSTEDT, U. (1971). Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta. Physiol. Scand., Suppl., 367, 69-93.